Basilea Pharmaceutica - Momentum continues
Basilea reported good momentum in H121 in all parts of the business. While total revenues declined to CHF54.2m (reflecting the phasing out of deferred revenues booked), actual in-market sales of Cresemba (severe mould infections) and Cresemba related income increased. Management has thus upgraded FY21 guidance for revenue to CHF134–144m (vs CHF128–138m) and operating loss to CHF7–17m (vs prior expected loss of CHF13–23m). We expect an event-driven 18 months ahead, with multiple R&D-related inflection points for its oncology assets derazantinib and lisavanbulin (glioblastoma). Basilea plans to progress a potential first-in-class kinase inhibitor into the clinic in early 2022, taking the oncology R&D pipeline tally to three assets. We value Basilea at CHF1.26bn.Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.